Drug Trial Radar · NCT07665450
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Sep 9, 2026
Primary completion
Sep 4, 2030
Study completion Feb 2, 2035
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jun 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to see how well a new treatment ramantamig-D works compared to standard treatments that is either DVRd or DRd on progression-free survival (PFS; time until a participant's disease worsens) and 12-month minimal residue disease (MRD)-negative complete response (CR) rate (percentage of participants in whom cancer cells are not detected) in participants with newly diagnosed multiple myeloma (NDMM; an initial stage of blood cancer that forms in a type of white blood cells \[WBCs\] called plasma cells) for whom stem cell transplant is not planned as initial therapy.
Conditions
- Multiple Myeloma
Interventions
RamantamigDrug
Ramantamig will be administered subcutaneously.
DaratumumabDrug
Daratumumab will be administered subcutaneously.
LenalidomideDrug
Lenalidomide will be administered orally.
BortezomibDrug
Bortezomib will be administered subcutaneously or intravenously.
DexamethasoneDrug
Dexamethasone will be administered orally or intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Up to approximately 62 months
- Percentage of Participants Achieving 12-Month Minimal Residual Disease (MRD)-Negative Complete Response (CR)Time frame: Up to 12 months
Locations
103 sites in 14 countries. Site status is shown where the registry gives one.
St Vincent s Hospital Sydney
Darlinghurst, Australia · Recruiting
Mater Hospital Brisbane
South Brisbane, Australia · Recruiting
Fakultni nemocnice Brno
Brno, Czechia · Recruiting
Fakultni nemocnice Hradec Kralove
Hradec Králové, Czechia · Recruiting
Fakultni Nemocnice Ostrava
Ostrava, Czechia · Recruiting
Fakultni nemocnice Plzen
Pilsen, Czechia · Recruiting
Fakultni nemocnice Kralovske Vinohrady
Prague, Czechia · Recruiting
Vseobecna fakultni nemocnice v Praze
Prague, Czechia · Recruiting
Hopital Claude Huriez
Lille, France · Recruiting
CHU de Montpellier Hopital Saint Eloi
Montpellier, France · Recruiting
CHU Nantes
Nantes, France · Recruiting
Aphp Hopital Saint Antoine
Paris, France · Recruiting
CHU de Bordeaux - Hospital Haut-Leveque
Pessac, France · Recruiting
CHU Lyon Sud
Pierre-Bénite, France · Recruiting
IUCT Oncopole Institut Claudius Regaud
Toulouse, France · Recruiting
CHRU Tours Hopital Bretonneau
Tours, France · Recruiting
CHU Nancy Brabois
Vandœuvre-lès-Nancy, France · Recruiting
St. Barbara-Klinik Hamm GmbH
Hamm, Germany · Recruiting
Universitaetsklinikum Wuerzburg
Würzburg, Germany · Recruiting
Uni General Hospital of Alexandroupolis
Alexandroupoli, Greece · Recruiting
Evangelismos S A
Athens, Greece · Recruiting
Laiko General Hospital of Athens
Athens, Greece · Recruiting
Alexandra General Hospital of Athens
Athens, Greece · Recruiting
Theageneio Cancer Hospital
Thessaloniki, Greece · Recruiting
Geniko Nosokomeio Thessalonikis George Papanikolaou
Thessaloniki, Greece · Recruiting
Rambam Med.Center - Hematology Institute
Haifa, Israel · Recruiting
Carmel Medical Center
Haifa, Israel · Recruiting
Shaare Zedek Medical Center
Jerusalem, Israel · Recruiting
Rabin Medical Center
Petah Tikva, Israel · Recruiting
Sheba Medical Center
Ramat Gan, Israel · Recruiting
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel · Recruiting
A O U Sant Orsola Malpighi
Bologna, Italy · Recruiting
S.C. Ematologia Azienda Ospedaliera S. Croce e Carle
Cuneo, Italy · Recruiting
Fondazione IRCCS Ca Granda Ospedale Policlinico Di Milano
Milan, Italy · Recruiting
Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
Palermo, Italy · Recruiting
Catharina Ziekenhuis
Eindhoven, Netherlands · Recruiting
Universitair Medisch Centrum Groningen
Groningen, Netherlands · Recruiting
Sint Antonius Ziekenhuis
Nieuwegein, Netherlands · Recruiting
Zuyderland Medical Center
Sittard-Geleen, Netherlands · Recruiting
UMCU
Utrecht, Netherlands · Recruiting
Showing 40 of 103 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.